Institutional Research Collaboration between the Liverpool School of Tropical Medicine and the Centers for Department of Health and Human Services Centers for Disease Control and Prevention

利物浦热带医学院与卫生与人类服务部疾病控制与预防中心之间的机构研究合作

• 批准号: 9335661
• 负责人: FEIKO OLAF TER KUILE
• 金额: $ 372.57万
• 依托单位: TMLIVERPOOL SCHOOL OF TROPICAL MEDICINE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9335661
• 关键词: Institutional; Research; Collaboration; between; Liverpool

Project summary This is the 3rd, 5-year collaborative agreement between CDC's Malaria Branch and the Liverpool School of Tropical Medicine (LSTM). The proposed research strategy follows the objectives outlined in the FOA and involves 4 themes: a) Operational research (OR) related to malaria transmission reduction, b) OR to identify novel or improved interventions for children with severe malarial anaemia and pregnant women, c) Maximising the public health impact by supporting translation of global policies for the control of malaria in pregnancy to country level policies through information exchange (3.1), and d) Strengthening research capacity of the overseas partners in Kenya, Malawi and Indonesia by provision of individual level PhD and post-doctoral studentships and group courses (5.1). Malaria transmission reduction OR activities take place under the umbrella of the long-term collaboration between the Kenya Medical Research Institute (KEMRI) and CDC in Kenya. LSTM will work with CDC to provide technical support to KEMRI to build the information infrastructure needed to track malaria transmission intensity and progress towards malaria control targets, including the rational development of large-scale entomological monitoring systems in situations with declining vector densities, increased outdoor biting and vector resistance to the commonly used insecticides (1.1), support the development of enhanced semi-automated routine surveillance systems with scannable registers, and conduct continuous malaria indicator surveys for real- time monitoring of the case-burden and infection prevalence (4.1). LSTM will support CDC to develop the concept and seek funding for proof-of-principle studies that determine the safety, feasibility and effectiveness of mass-drug administration with antimalarials when combined with indoor residual spraying (2.1). It will support dose finding studies with primaquine and ivermectin that aim to identify adjunct therapies to enhance the impact of mass drug administration (MDA) (2.2), and support the economic evaluation of different interventions and surveillance methods as part of the transmission reduction activities (2.3). Studies in high risk groups includes research to improve adherence to malaria case-management guidelines in pregnancy in western Kenya (1.2) and three large multi-centre trials including one on the prevention of rebound admissions and deaths with post-discharge malaria chemoprevention in children with severe anaemia in Kenya (2.4) and two on the control of malaria in pregnancy: STOPMiP-Indonesia (2.6), STOPMIP2 in Kenya and Malawi (2.5) evaluating the safety and efficacy of intermittent preventive therapy with dihydroartemisinin-piperaquine.

项目概要 这是疾病预防控制中心疟疾处与美国疾病预防控制中心之间的第三个为期五年的合作协议 利物浦热带医学院 (LSTM)。拟议的研究策略遵循 FOA 中概述的目标涉及 4 个主题： a) 与以下方面相关的运筹研究 (OR)： 减少疟疾传播，b) 或确定针对儿童的新颖或改进的干预措施 严重疟疾贫血和孕妇，c) 最大限度地提高公共卫生影响 支持将控制妊娠期疟疾的全球政策转化为各国 通过信息交流制定政策（3.1），以及 d) 加强研究能力 肯尼亚、马拉维和印度尼西亚的海外合作伙伴，提供个人级别的博士学位 以及博士后奖学金和团体课程（5.1）。减少疟疾传播或 活动是在肯尼亚与肯尼亚之间的长期合作的框架下进行的 肯尼亚医学研究所 (KEMRI) 和疾病预防控制中心 (CDC)。 LSTM 将与 CDC 合作提供 为 KEMRI 提供技术支持，以建立追踪疟疾所需的信息基础设施 传播强度和实现疟疾控制目标的进展，包括合理的疟疾控制目标 在昆虫数量下降的情况下开发大规模昆虫监测系统 病媒密度，增加户外咬食和病媒对常用药物的抵抗力 杀虫剂（1.1），支持发展增强型半自动常规监测 具有可扫描登记册的系统，并进行连续的疟疾指标调查，以了解实际情况 及时监测病例负担和感染率（4.1）。 LSTM 将支持 CDC 开发概念并为确定安全性的原理验证研究寻求资金， 大规模给药与抗疟药联合使用的可行性和有效性 室内滞留喷洒（2.1）。它将支持伯氨喹和 伊维菌素旨在确定辅助疗法以增强大规模药物的影响 管理（MDA）（2.2），并支持不同干预措施的经济评估 和监测方法作为减少传播活动的一部分（2.3）。高等研究 风险群体包括提高对疟疾病例管理指南的遵守程度的研究 肯尼亚西部的妊娠试验（1.2）和三项大型多中心试验，其中一项是关于 通过出院后疟疾化学预防预防反弹入院和死亡 肯尼亚患有严重贫血的儿童（2.4）和妊娠期疟疾控制方面的两个： STOPMiP-印度尼西亚 (2.6)、肯尼亚和马拉维的 STOPMIP2 (2.5) 评估安全性和 双氢青蒿素哌喹间歇性预防治疗的疗效。